Supplementary Materials

The PDF file includes:

  • Fig. S1. Evaluation and validation of a rescue genome-wide siRNA screen.
  • Fig. S2. Top hits from a secondary deconvoluted siRNA screen.
  • Fig. S3. SP3, and not SP1, is required for SMC efficacy in cancer cells.
  • Fig. S4. Knocking down SP3 does not prevent cell death induced by cycloheximide, staurosporine, or VP16.
  • Fig. S5. Expression of cytokines and chemokines that are modulated by SP3 in SMC-treated cancer cells.
  • Fig. S6. SMC treatment does not affect the DNA binding activity of SP3.
  • Fig. S7. SMC-induced cancer cell death is prevented by shRNA-mediated knockdown of SP3.
  • Fig. S8. SP3 deficiency does not induce cancer cell death upon cotreatment with SMCs and TNF-α.
  • Fig. S9. SP3 is the major transcription factor involved in promoting SMC-mediated cancer cell death.
  • Fig. S10. SP3 overexpression in normal cells leads to cytotoxicity.
  • Fig. S11. Overexpression of SP3 does not lead to cell death in SMC-resistant cell lines.
  • Fig. S12. cFLIP and SP3 are critical mediators for SMC efficacy in resistant cancer cells.
  • Fig. S13. Full-length Western blots.
  • Table S1. Data from siRNA screen.
  • Legend for table S2.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S2 (Microsoft Excel format). Primer sequences.